Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | TNKS | O95271 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3671074 | 1.00 | NFE2L2 (0.53) | NFE2L2EGFRMMP1MMP2MMP9 | |
| SCHEMBL3671136 | 0.84 | CYP1B1 (0.53) | GPR183KMT2ALMNAALDH1A1TRPA1 | |
| SCHEMBL3671132 | 0.84 | CYP1B1 (0.53) | GPR183KMT2ALMNAALDH1A1TRPA1 | |
| SCHEMBL3673698 | 0.84 | MAOB (0.53) | EGFRMMP1MMP2MMP9L3MBTL1 | |
| SCHEMBL3673702 | 0.84 | MAOB (0.53) | EGFRMMP1MMP2MMP9L3MBTL1 | |
| SCHEMBL210090 | 0.78 | MAPT (0.50) | EGFRMMP1MMP2MMP9KMT2A | |
| SCHEMBL2622602 | 0.76 | NFE2L2 (0.61) | NFE2L2EGFRMMP1MMP2MMP9 | |
| SCHEMBL940841 | 0.75 | HDAC3 (0.47) | EGFRMMP1MMP2MMP9KMT2A | |
| SCHEMBL2480621 | 0.75 | MAPT (0.47) | EGFRMMP1MMP2MMP9KMT2A | |
| SCHEMBL18867936 | 0.72 | NFE2L2 (1.00) | NFE2L2MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1223923-B1 | UNSATURATED ARYL SULFONES FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2010-03-31 | — | — | EP | disclosed |
| US-7595347-B2 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | Temple University—Of the Commonwealth System of Higher Education (US) | 2009-09-29 | — | — | US | disclosed |
| EP-1370253-B1 | USE OF ALPHA, BETA UNSATURATED ARYL SULFONES FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY | UNIV TEMPLE (US) | 2008-09-03 | — | — | EP | disclosed |
| EP-1223923-A4 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | UNIV TEMPLE (US) | 2007-09-05 | — | — | EP | disclosed |
| EP-1027330-B1 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | COSENZA STEPHEN C (US) | 2004-10-28 | — | — | US | disclosed |
| US-6767926-B1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2004-07-27 | — | — | US | disclosed |
| US-6667346-B2 | Administration of a radioprotective alpha, beta unsaturated aryl sulfone compound to a patient prior to anticancer radiotherapy reduces cytotoxic side effects of radiation on normal cells | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-23 | — | — | US | disclosed |
| US-6656973-B2 | Anticancer chemotherapy, and cytoprotective agents administered before, during or after chemotherapy to protect the normal cells of the patient | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-12-02 | — | — | US | disclosed |
| EP-1027330-A4 | STYRYL SULFONE ANTICANCER AGENTS | UNIV TEMPLE (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | COSENZA STEPHEN C (US) | 2003-08-07 | — | — | US | disclosed |
| US-20030114538-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2003-06-19 | — | — | US | disclosed |
| US-6548553-B2 | Therapy of proliferative disease other than prostate or breast cancer comprising administering styryl sulfone derivative | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2003-04-15 | — | — | US | disclosed |
| EP-1223923-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2002-07-24 | — | — | EP | disclosed |
| US-6359013-B1 | BREAST AND PROSTATE CANCER; AFFECT THE MAPK SIGNAL TRANSDUCTION PATHWAY, THEREBY TUMOR CELL GROWTH; INHIBIT THE GROWTH OF TUMOR CELLS WITHOUT AFFECTING NORMAL CELLS; 4-FLUOROSTYRYL 4-BROMOBENZYL SULFONE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-03-19 | — | — | US | disclosed |
| US-20020022666-A1 | Styryl sulfone anticancer agents | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION | 2002-02-21 | — | — | US | disclosed |
| WO-2001026645-A1 | METHOD FOR PROTECTING NORMAL CELLS FROM CYTOTOXICITY OF CHEMOTHERAPEUTIC AGENTS | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2001-04-19 | — | — | WO | disclosed |
| WO-2000059494-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY- OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2000-10-12 | — | — | WO | disclosed |
| EP-1027330-A1 | STYRYL SULFONE ANTICANCER AGENTS | Temple University of the Commonwealth System of Higher Education (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1999018068-A1 | STYRYL SULFONE ANTICANCER AGENTS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114538-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | NFE2L2 130/4885EGFR 264/4885MMP1 3397/4885 |
| US-20040214903-A1 | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents | TOP1, TOP2A, PCNA | NFE2L2 104/4885EGFR 3709/4885MMP1 2240/4885 |
| US-20020022666-A1 | Styryl sulfone anticancer agents | BCL2, MCL1, BCL2A1 | NFE2L2 130/4885EGFR 264/4885MMP1 3397/4885 |
| US-20030149109-A1 | (E)-4-carboxystyrl-4-chlorobenzyl sulfone and pharmaceutical compositions thereof | CCNE1, CCNE2, TOP2B | NFE2L2 119/4885EGFR 1728/4885MMP1 3690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.